In last trading session, Marinus Pharmaceuticals Inc (NASDAQ:MRNS) saw 0.31 million shares changing hands with its beta currently measuring 1.15. Company’s recent per share price level of $1.47 trading at $0.01 or 0.34% at ring of the bell on the day assigns it a market valuation of $80.47M. That closing price of MRNS’s stock is at a discount of -665.99% from its 52-week high price of $11.26 and is indicating a premium of 24.49% from its 52-week low price of $1.11. Taking a look at company’s average trading volume volume of 2.14 million if we extend that period to 3-months.
Marinus Pharmaceuticals Inc (NASDAQ:MRNS) trade information
Upright in the green during last session for gaining 0.34%, in the last five days MRNS remained trading in the red while hitting it’s week-highest on Wednesday, 06/12/24 when the stock touched $1.47 price level, adding 10.09% to its value on the day. Marinus Pharmaceuticals Inc’s shares saw a change of -86.52% in year-to-date performance and have moved -3.62% in past 5-day. Marinus Pharmaceuticals Inc (NASDAQ:MRNS) showed a performance of 10.15% in past 30-days.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Marinus Pharmaceuticals Inc (MRNS) estimates and forecasts
Statistics highlight that Marinus Pharmaceuticals Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -83.37% of value to its shares in past 6 months, showing an annual growth rate of 28.90% while that of industry is 14.20. Apart from that, the company came raising its revenue forecast for fiscal year 2024.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 6.04% during past 5 years. In 2024, company’s earnings growth rate is likely to be around 25.30% while estimates for its earnings growth in next 5 years are of 20.00%.
MRNS Dividends
Marinus Pharmaceuticals Inc is more likely to be releasing its next quarterly report in July and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
